|Day Low/High||41.83 / 42.62|
|52 Wk Low/High||34.32 / 46.47|
Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.
Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).
U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...
Stocks ended lower on weakness in tech shares and after a strong report from Caterpillar proved insufficient to prop up the Dow.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
U.S. companies are on pace for one of the best earnings seasons in a decade, according to mid-term data from FactSet, with most firms appearing to have little or no concern for the impact of trade and tariffs on their bottoms lines over the coming months.
Shares fell on Friday morning despite positive results for the second quarter.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
Pfizer today announced it will increase its commitment to U.S.
ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...
ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Pfizer Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #110 spot out of 500.
These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.
The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.
Pfizer Inc. (NYSE:PFE) today announced that the United States (U.
Drug pricing remains front and center as healthcare companies start reporting quarterly results.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met...
Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.
From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.
This market is all about being opportunistic.
Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.
The most recent short interest data has been released for the 06/29/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Here's what you need to know now for Wednesday, July 11.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.